Multiple Factors Suggest Genzyme Still Faces Cerezyme Production Problems
Executive Summary
In the weeks since Genzyme announced the shutdown of its Allston Landing, Mass., production facility because of viral contamination, the actual severity of the problem has been much debated. On Aug. 10, investors and industry watchers gleaned more about the true extent of the problem, with the Cambridge, Mass.-based big biotech's announcement it had discarded roughly 80 percent of the work-in-process material for Cerezyme (imiglucerase) that remained from when the Allston plant was closed for decontamination in mid-June
You may also be interested in...
Genzyme Says Work At Allston Plant Will Resume As Planned Later This Month
Viral contamination in one of the plant's bioreactors caused a complete shutdown, stopping new production of Cerezyme and Fabrazyme.
Shortage Could Cause Early Access To Developmental Gaucher Disease Drugs
Shire and Protalix BioTherapeutics' experimental Gaucher disease drugs could enter the market early to help offset likely treatment shortages created by manufacturing problems with the only enzyme replacement therapy currently approved for the orphan condition: Genzyme's Cerezyme
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011